Emr200647-001- A Phase I, Open-Label, Multiple-Ascending Dose Trial To Investigate The Safety, Tolerability, Pharmacokinetics, Biological And Clinical Activity Of Msb0011359c In Subjects With Metastatic Or Locally Advanced Solid Tumors And Expansion To Se
Posted Date: Jun 17, 2019
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to determine the safety, tolerability,and the maximum-tolerated dose of MSB0011359C in subjects with metastatic or locally advanced solid tumors, and assess the best overall response according to Response Evaluation Criteria in Solid Tumors.
Criteria:
To Be Eligible: Must Be Age 18 Or Older, Life Expentancy >12 Weeks, Nonpregnant/Breastfeeding, No Previous Malignant Disease Within 3 Years, No Severe Infections
Keywords:
Tumors, Cancer, Phase I
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com